Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1687 • ACR Convergence 2024
IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Ioannis Parodis¹, Dionysis Nikolopoulos², Julius Lindblom³, Denis Lagutkin³, Lorenzo Beretta⁴, Maria Orietta Borghi⁵, Janique Peyper⁶, Guillermo Barturen⁷, Per-Johan Jakobsson³, Marta Alarcon-Riquelme⁸, Natalia Sherina³ and Helena Idborg⁹, and PRECISESADS Clinical Consortium, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁵Università degli Studi di Milano Statale, Milano, Italy, ⁶Sengenics Corporation Pte Ltd, Singapore, Singapore, ⁷Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁸Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁹Karolinska Institutet, Solna, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
Abstract Number: 1770 • ACR Convergence 2024
Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus
Nalani Sachan¹, Christina Firl², Philip Carlucci³, Nicola Fraser², Robert Clancy⁴ and Jill Buyon⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL), driven by fetal exposure to maternal anti-SSA/Ro autoantibodies, typically results in permanent cardiac manifestations in utero and/or a transient rash postnatally.…
Abstract Number: 1799 • ACR Convergence 2024
In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
Jia Xin Chow¹, Rochelle Sherlock², Taylah Bennett², Eric Morand³ and Sarah Jones², ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Australia, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The strategy of inhibiting toll-like receptors (TLR) 7 and 8 is being evaluated in clinical trials in systemic lupus erythematosus (SLE) to assess its…
Abstract Number: 1876 • ACR Convergence 2024
Automated Case Identification of Patients with End-Stage Renal Disease and Systemic Lupus Erythematosus Using Machine Learning
Mario Felix¹ and Lais Osmani², ¹Yale, Hamden, CT, ²Yale, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease, with 4-28% of patients developing End-Stage Renal Disease (ESRD). Accurate identification of these patients is…
Abstract Number: 2170 • ACR Convergence 2024
Preliminary Evaluation of a Patient-Reported Version for the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): The Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAQ)
Patti Katz¹, Amanda Eudy², Sarah Patterson³, Jennifer Rogers⁴, David Pisetsky⁵, Megan Clowse⁶ and Maria Dall'Era⁷, ¹UCSF, San Rafael, CA, ²Duke University, Raleigh, NC, ³University of California San Francisco, San Francisco, CA, ⁴Duke University, Durham, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Chapel Hill, NC, ⁷UCSF, Corte Madera, CA
Background/Purpose: Much of the evidence demonstrating the impact of systemic lupus erythematosus (SLE) on patients’ lives, functioning, and quality of life has come from observational…
Abstract Number: 2383 • ACR Convergence 2024
Outcomes of Systemic Lupus Erythematosus Hospitalizations: Insights from a Multinational Tertiary Center Experience
Miral Gharib¹, Karima Becetti¹, Hana J.Abukhadijah², Fiaz Alam¹, Aishwariya Padmakumari³, Mohamed Awni AlKahlout³, rawan sheikh saleh¹, Muhammad Bilal Jamshaid⁴ and Samar Alemadi⁵, ¹hamad medical corporation, Doha, Qatar, ²Hamad medical corporation, doha, Ad Dawhah, Qatar, ³HMC, Doha, Qatar, ⁴Hamad Corp - Hamad General Hospital, Al sadd, Qatar, ⁵Hamad medical corporation, Doha, Qatar
Background/Purpose: Systemic Lupus Erythematosus is characterized by diverse clinical presentations and a remarkably unpredictable course. Although survival rate has increased in recent decades, morbidity and…
Abstract Number: 2402 • ACR Convergence 2024
Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
Marta Mosca¹, Karen Costenbader², Joan Merrill³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald Van Vollenhoven⁹, ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: SLE flares are associated with increased risk of organ damage/mortality; flare prevention is a key treatment goal.1 Initiating treatment earlier has benefits in autoimmune…
Abstract Number: 2419 • ACR Convergence 2024
Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data
Richard Furie¹, Mawuena Binka², Gelareh Atefi³, Stephanie Y. Chen⁴ and Bo Ding⁵, ¹Northwell Health, Manhasset, NY, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ³AstraZeneca, Media, PA, ⁴BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: SLE is an autoimmune disease with diverse manifestations and progression patterns that, via disease activity and effects of standard therapy, imposes a significant burden…
Abstract Number: 2436 • ACR Convergence 2024
Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
Florian Kollert¹, Sarah Robertson², Veit Erpenbeck², Franziska Regenass-Lechner³, Remy Hallet³, Jason Neale², Cary M. Looney², Nicolas Frances², Celine Marban-Doran², Sophia Fredrika Soehrman Brossard², Laurie Millar⁴, Beki Finch⁵, Johannes Sam⁶, Benjamin A. Fisher⁷, Maria Leandro⁸, Thomas Dörner⁹, Christian Klein¹⁰ and Franz Schuler², ¹University Hospital Basel, Basel, Switzerland, ²F. Hoffmann-La Roche Ltd., Basel, Switzerland, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴F. Hoffmann-La Roche Ltd., Welwyn Garden City, England, United Kingdom, ⁵F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom, ⁶F. Hoffmann-La Roche Ltd, Schlieren, Zurich, Switzerland, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University College London, London, United Kingdom, ⁹Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ¹⁰F. Hoffman-La Roche Ltd., Schlieren, Zurich, Switzerland
Background/Purpose: CD20-directed B-cell depletion therapy shows efficacy in hematological malignancies and in multiple autoimmune indications. More recently, promising data for the use of CD19-targeted B-cell…
Abstract Number: 2592 • ACR Convergence 2024
The Effects of Early Life Trauma and Socioeconomic Position on Systemic Lupus Erythematosus Risk in Adulthood
Jennifer Woo¹ and Dale Sandler², ¹Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, NC, ²Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC
Background/Purpose: Early life trauma (ELT) and neighborhood deprivation (ND)—a measure of socioeconomic position (SEP)—represent two aspects of the early life social environment that can be…
Abstract Number: 2679 • ACR Convergence 2024
Predictors of Fracture in SLE: A Longitudinal Cohort Study
Kristen Chao¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Fractures are one of the most common damage items in the SLICC/ACR Damage Index. Although commonly attributed to corticosteroid use, the complexity of ways…
Abstract Number: 0086 • ACR Convergence 2024
Evaluating the Efficacyof B Cell Targeting Drug Candidates Using a Humanized BAFF Transgenic SLE Mouse Model
Juan Liang, Shuxin Xu, Qiuping Xu and Yuxi Zhang, GemPharmatech, San Diego
Background/Purpose: B-cell-activating factor (BAFF) plays a critical role in B cell survival, and its elevated expression can contribute to the presence of autoreactive B cells,…
Abstract Number: 0145 • ACR Convergence 2024
Community Mobility in a Diverse Cohort of Individuals with Systemic Lupus Erythematosus
Leila Milanfar¹, Jinoos Yazdany², Amanda Eudy³, Courtney Hoge⁴, Charmayne M. Dunlop-Thomas⁵, Patti Katz⁶ and Laura Plantinga⁷, ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Duke University, Raleigh, NC, ⁴Emory University, Atlanta, GA, ⁵Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁶UCSF, San Rafael, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Measurement of the extent to which individuals move throughout their community and participate in social activities (“community mobility”) can provide a snapshot of how…
Abstract Number: 0187 • ACR Convergence 2024
Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
Abstract Number: 0255 • ACR Convergence 2024
“Rheum” to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative
Razan Al Yaarubi¹, Amanda Steiman¹ and Earl Silverman², ¹University of Toronto, Toronto, ON, Canada, ²Silverman, Toronto, ON, Canada
Background/Purpose: Infections are a leading cause of morbidity and mortality in patients with childhood-onset systemic lupus erythematosus (cSLE). Vaccination is a powerful tool to prevent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].